

## Section III - 510(k) Summary of Safety and Effectiveness

## Submitter:

OCT - 7 2009

Sybron Dental Specialties, Inc. 1717 W. Collins Avenue Orange, California 92867 (714) 516-7602 - Phone (714) 516-7488 - Facsimile Wendy Garman - Contact Person

Date Summary Prepared:

September 2009

#### Device Name:

- Trade Name Take 1
- Common Name Dental Impression Material
- Classification Name Impression Material, per 21 CFR § 872.3660

## Devices for Which Substantial Equivalence is Claimed:

Kerr Corporation, Kerr VPS Impression Material

#### Device Description:

The device is an addition-cure vinyl polysiloxane dental impression material that is used for all crowns and bridges, edentulous, orthodontic and implant impression techniques. Take 1 is a two-part, base/catalyst – paste/paste system. The product is available in three viscosities, Wash, Tray, and Medium.

#### Intended Use of the Device:

Take 1 is an addition-cure vinyl polysiloxane dental impression material that is used for all crown and bridge, edentulous, orthodontic and implant impression techniques.

#### Substantial Equivalence:

Take 1 is substantially equivalent to other legally marketed devices in the United States. Take 1 functions in a manner similar to and is intended for the same use as Kerr VPS Impression Material that is currently manufactured by Kerr Corporation:

# **DEPARTMENT OF HEALTH & HUMAN SERVICES**



Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002

OCT - 7 2009

Kerr Corporation C/O Ms. Colleen Boswell Director, Regulatory Affairs Sybron Dental Specialties, Incorporated 1717 West Collins Avenue Orange, California 92867

Re: K091613

Trade/Device Name: Take 1

Regulation Number: 21 CFR 872.3660 Regulation Name: Impression Material

Regulatory Class: II Product Code: ELW Dated: October 2, 2009 Received: October 5, 2009

# Dear Ms. Boswell:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please contact the CDRH/Office of Surveillance and Biometrics/Division of Postmarket Surveillance at 240-276-3464. For more information regarding the reporting of adverse events, please go to <a href="http://www.fda.gov/cdrh/mdr/">http://www.fda.gov/cdrh/mdr/</a>.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours,

Susan Runner, D.D.S., M.A.

Acting Director

Division of Anesthesiology, General Hospital, Infection Control and Dental Devices

Office of Device Evaluation

Center for Devices and

Radiological Health

# **Indications for Use**

510(k) Number (if known):

Device Name: Take 1		
Indications For Use:		
Take 1 is an addition-cure vinyl po all crown and bridge, edentulous,	olysiloxane dental im orthodontic and impl	pression material that is used for ant impression techniques.
	.*	
Prescription Use	AND/OR	Over-The-Counter Use
(Part 21 CFR 801 Subpart D)		(21 CFR 807 Subpart C)
(PLEASE DO NOT WRITE BELCIF NEEDED)	OW THIS LINE - CO	ONTINUE ON ANOTHER PAGE
Concurrence of CD	RH, Office of Device	e Evaluation (ODE)
(Division Sign-Off) Division of Anesthesiolog		Page 1 of <u>1</u>
510(k) Number: <u>K</u> C	91613	